We have recently published a list The best stocks to get by Jim Simons’ Renaissance Technologies In this article, ITTEX Pharmaceuticals (NASDAQ: VRTX), JIM Simons will take a look at the location of the other best shares to get according to the Renaissance Technology.
After 2024, billionaire investor and mathematician Jim Simons are known as “king of Hedge” due to extraordinary success Renaissance technologiesThe quantitative trading company located in New York. After examining the financial industry, Simons, the use of the unprocessed potential for market analysis to capitalize the market inefficiency. This idea has led to a managed investment strategy to analyze market behavior using statistical and mathematical models. By identifying fine, non-random samples in financial information, Genius predicted future shareholders and brought effective income.
Although foreign investors are attached to the CIM Simons’ Treaty Medallion Hedge Foundation, the floating flagship, resulted in the result of the result of the launch. The Medallion Foundation continued in the early 2000s in early 2000s and a global financial crisis between 56.6% and 74.6%, 74.6%, 74.6% and 2007-201 and 10.5% of the first two years. During his death, the strong market implementation of the Medallion Foundation and Renaissance was worth $ 31.4 billion among the world’s richest people.
Renaissance Technologies’ computer-controlled power plant came out of a start after a perfect performance in 2024. 11.85% in the first two months of 2025. Both funds are allowed to protect a fund’s stock positions to help manage stock index futures and risk. However, the company warns that these size holdings can be difficult to open quickly without affect market prices.
According to this list, by the end of the fourth quarter of 2024, we chose shares from the 13F portfolio of Renaissance technologies. These capital are also popular among elite hedge funds.
Why are we interested in the stocks that collect hedgehogs? The reason is simple: Our research has shown that we can top the market by imitating the best stock options of the best hedge funds. Our quarterly Newsletter strategy selects 14 small lids and large caps in each quarter and elected 373.4% by defeating the bench from May 218 percent in May 2014 (See more information here).
Vrtex Pharmaceuticals (VRTX) is the best share of Jim Simons to buy according to Renaissance technologies?
A pharmacist who presents a special drug to a patient who takes a special medicine.
Renaissance Technologies Q4 Stake: $ 562.6 million
Number of Hedge Founders: 58
The specified vertex pharmaceutical (NASDAQ: VRTX) is a global biotechnology company involved in the discovery and development of small molecule for severe diseases, including cystic fibrosis.
Vertex pharmaceuticals reported in the first quarter reduced consensus forecasts of the combined (NASDAQ: VRTX), Alyftrek and Journavx drugs. Nevertheless, the company expressed confidence in future growth by increasing the lower end of the financial management.
On May 7, Bernstein analysts, while maintaining markets, while continuing the rating (NASDAQ: VRTX) Repeated $ 462 for Nasdaq: VRTX). The shares on May 6 offer a cautious approach to the company, which is a 10% decline and the importance of the importance of clinical trials, offers a careful approach to the company that determines the trajectory of the company.
Management of the greenery assets, including the following in connection with VERTEX pharmaceutical products Q1 2025 Investor Letter:
“Vertex Pharmaceuticals included (NASDAQ: VRTX) The second best performer in the quarter, + 20.4%. The growing demand for cystic fibrosis (CF) franchise continued to create a significant free cash flow. Vertex diversify the product portfolio and launched two newly approved therapy recently: Alyftrek and Jouravx. Alyfrtek is a VRTX CF portfolio that offers a daily dosage mode that is more affordable for patients. The important thing is that the previous treatment covers 31 additional unique mutations of CF. Non-opioid pain for acute pain begins to increase sales because doctors gain confidence in the effectiveness of doctors and meet VRTX payers, Journavx has the potential to become a significant improvement in patients. In addition, the VRTX prevented the transfer of pain signals for chronic pain, which uses a similar mechanism of Action-blocked selective sodium sodium channels, less target effects. Success would be excellent news for shareholders, but even more importantly, the opioids offer a strong alternative to the opioid and help fight against the opioid crisis. “
In general, vrtx Ranks 7 Jim Simons’ in our list of the best shares to buy according to Renaissance Technologies. While accepting the potential of VRTX as an investment, our belief is in the belief that some AI shares promise to give rise to higher income and return more in a shorter period. Since the beginning of 2025, popular AI shares have an EU reserve that lost about 25%. If you are looking for an AI stock that is more promising than VRTX, if you trade less than 5 times the earnings, review our report Cheap EU reserves.
